Entinostat (MS-275)

製品コードS1053 別名:SNDX-275

Entinostat (MS-275)化学構造

分子量(MW):376.41

Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.

サイズ 価格(税別)  
JPY 17100
JPY 13600
JPY 26900
JPY 46800
JPY 129800
最寄りの販売代理店を探す

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください:[email protected]

バルク問合せ

文献中Selleckの製品使用例(90)

製品安全説明書

HDAC阻害剤の選択性比較

生物活性

製品説明 Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.
ターゲット
HDAC1 [2]
(Cell-free assay)
HDAC3 [2]
(Cell-free assay)
0.51 μM 1.7 μM
体外試験

MS-275 shows inhibitory to HDACs by 2'-amino group. MS-275 induces accumulation of p21WAF1/CIP1 and gelsolin in K562 cell. MS-275 could reduce S-phase cells and induce G1-phase cells in A2780 cell. MS-275 inhibits the proliferation of human tumor cell lines including A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 with IC50 from 41.5 nM to 4.71 μM, which due to HAD-inhibition. [1] MS-275 is not sensitive to other HDACs (4, 6, 8 and 10) with IC50 about/above 100 μM. [2] MS-275 shows great inhibition to human leukemia and lymphoma cells, including U937, HL-60, K562, and Jurkat. MS-275 also decreases expression of cyclin D1 and the antiapoptotic proteins Mcl-1 and XIAP. [3]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SCC-3 M3zTb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTBwME[xJO69VQ>? Ml\CV2FPT0WU
ALL-PO NHexc2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPUWolvUUN3ME2wMlA3OzV3IN88US=> M3K5SHNCVkeHUh?=
697 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTBwMEm5O|Yh|ryP MnTYV2FPT0WU
NCI-H748 Mk\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7neVVKSzVyPUCuNVA{OzRizszN MmLqV2FPT0WU
NKM-1 NXvvNYhyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rPU2lEPTB;MD6xNFkyOiEQvF2= NGD6UWlUSU6JRWK=
ES1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjVTWM2OD1yLkGxNlU2KM7:TR?= MWHTRW5ITVJ?
NCI-H1963 Ml60S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTBwMUG1O|kh|ryP MYLTRW5ITVJ?
NCI-H1417 M3Ttdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3afFVKSzVyPUCuNVI6PzRizszN MYnTRW5ITVJ?
NEC8 MlmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnf1TWM2OD1yLkGzOVI4KM7:TR?= Mm\UV2FPT0WU
CRO-AP2 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfKO4w2UUN3ME2wMlE3QDh7IN88US=> NXG2fXV3W0GQR1XS
A3-KAW MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTBwMUe2Nlch|ryP M4Xr[HNCVkeHUh?=
SF539 MlHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTBwMUm1PVMh|ryP MWHTRW5ITVJ?
NOS-1 NUe4VphvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HhTmlEPTB;MD6xPVYyQSEQvF2= Mn\iV2FPT0WU
NTERA-S-cl-D1 NXG0TlZCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHK3UHBKSzVyPUCuNlAyOTNizszN NFHNd3FUSU6JRWK=
COR-L88 NXXvVIhDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vFZWlEPTB;MD6yNlk2QSEQvF2= MmewV2FPT0WU
EM-2 M{jtfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPsSWFKSzVyPUCuNlQxPzlizszN NHvxbnNUSU6JRWK=
KARPAS-45 NV;0UGJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHoTWM2OD1yLkK3PFM{KM7:TR?= M4PKR3NCVkeHUh?=
DSH1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPJbmhbUUN3ME2wMlI5PzB6IN88US=> NWm2fINOW0GQR1XS
HT-144 NYm0bopFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3z3SGlEPTB;MD6zNFI2PiEQvF2= Mmf0V2FPT0WU
ATN-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\QfWlEPTB;MD6zNFU4PiEQvF2= NGnQ[oxUSU6JRWK=
HEL MnT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\TUYlwUUN3ME2wMlMyOzR6IN88US=> M{TmU3NCVkeHUh?=
NB12 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\QS2lEPTB;MD6zNVc2PiEQvF2= NVGxPZJJW0GQR1XS
LU-139 M2XUXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTBwM{O1NUDPxE1? MlTQV2FPT0WU
J-RT3-T3-5 NE\rXllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LVcGlEPTB;MD6zN|cyPiEQvF2= NELxTY5USU6JRWK=
MOLT-13 MkHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTBwM{O4NUDPxE1? M3i1VHNCVkeHUh?=
SR MlG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NET0dGlKSzVyPUCuN|QzPjFizszN M3u5OXNCVkeHUh?=
CMK M1HyWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfMW3JsUUN3ME2wMlM2PzJ5IN88US=> MYfTRW5ITVJ?
ES8 M4\EXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPPZm5EUUN3ME2wMlM3ODJ{IN88US=> MWDTRW5ITVJ?
LB647-SCLC MmnhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLKTWM2OD1yLkO2O|Mh|ryP NEDLVpJUSU6JRWK=
TE-8 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVr4dol3UUN3ME2wMlM3QTN3IN88US=> M1X1XHNCVkeHUh?=
BV-173 MkL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTBwM{exNlEh|ryP NFfxUINUSU6JRWK=
DEL NHrCc5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XGO2lEPTB;MD6zO|Q5PyEQvF2= NU\a[2JrW0GQR1XS
ARH-77 NYD0Xpg4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnSwTWM2OD1yLkO4NVk{KM7:TR?= NVHyTHVFW0GQR1XS
NCCIT NW\sV3hsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXe5Z|dLUUN3ME2wMlM5PjR7IN88US=> NW\PTHNzW0GQR1XS
RPMI-8402 NW\hdmJMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHETWM2OD1yLkO4O|AyKM7:TR?= NV7sXWN4W0GQR1XS
MONO-MAC-6 M4DRUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWr2cJJWUUN3ME2wMlM5Pzd4IN88US=> M3\uU3NCVkeHUh?=
SK-MM-2 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zSZ2lEPTB;MD6zPVg3QCEQvF2= MV7TRW5ITVJ?
CHP-126 M2PFT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;hVWlEPTB;MD60NFI{OSEQvF2= MYrTRW5ITVJ?
A101D NGfhWFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DxOGlEPTB;MD60NFMh|ryP M13xfnNCVkeHUh?=
SCH NU\ib5VyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1G5emlEPTB;MD60NFM1OiEQvF2= MYfTRW5ITVJ?
NMC-G1 NWPHVWhIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHsZXFKSzVyPUCuOFA{PjdizszN MnfyV2FPT0WU
NCI-H209 NGGxV4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfxe4J6UUN3ME2wMlQxPjF|IN88US=> NIHoXm9USU6JRWK=
MOLT-16 MnL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHObWliUUN3ME2wMlQyODF5IN88US=> NUPFOmRRW0GQR1XS
RPMI-6666 M3XOV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PHeWlEPTB;MD60NVEzKM7:TR?= NGH0Z|JUSU6JRWK=
OPM-2 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\BNmlEPTB;MD60NVUyOyEQvF2= M4CzOnNCVkeHUh?=
MRK-nu-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTBwNEOxOVMh|ryP NFHUTFNUSU6JRWK=
BC-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LHNGlEPTB;MD60N|QxOyEQvF2= NWLPV2p6W0GQR1XS
MHH-NB-11 NIHhVYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIG4eo1KSzVyPUCuOFM1PTNizszN MlXqV2FPT0WU
Ramos-2G6-4C10 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTBwNEO4PVch|ryP M1zSfnNCVkeHUh?=
LS-513 NFyy[FBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTETnNKSzVyPUCuOFQ2ODFizszN NXTyVWpGW0GQR1XS
K5 M1HTcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDKNnlnUUN3ME2wMlQ4ODJ3IN88US=> NYPMUZBvW0GQR1XS
HOP-62 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTBwNEizOVgh|ryP NYe4dWFbW0GQR1XS
NCI-H187 NFr5eW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\wcHZKSzVyPUCuOFkzOjdizszN NVXzRXhIW0GQR1XS
BE-13 Ml3JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTBwNEm2OlEh|ryP NIHsN4xUSU6JRWK=
HC-1 MlLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTBwNUC0O|Mh|ryP M4PlRXNCVkeHUh?=
ACN NYrUXGZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfjTWM2OD1yLkWxNFI5KM7:TR?= MoP6V2FPT0WU
HCC1599 NXjJdlV5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PvUGlEPTB;MD61NVU4KM7:TR?= MmPkV2FPT0WU
MV-4-11 M1XaeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XJVWlEPTB;MD61N|A1OSEQvF2= NWnnO4F2W0GQR1XS
LC-2-ad NYfmcJlvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33rS2lEPTB;MD61N|Y3OyEQvF2= MlvpV2FPT0WU
HL-60 NVfrdnVMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXuwZpRXUUN3ME2wMlU1OjZzIN88US=> NGfKfJZUSU6JRWK=
NB17 NIfFT|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mkf3TWM2OD1yLkW0N|gh|ryP MoT2V2FPT0WU
TE-1 M{nRemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mny1TWM2OD1yLkW1N|A3KM7:TR?= NEPZOmxUSU6JRWK=
NCI-H524 M3\tWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vieWlEPTB;MD61OVQxOSEQvF2= M3nsdnNCVkeHUh?=
MZ7-mel NGfPdZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3YempKSzVyPUCuOVYyODVizszN NEjzV4xUSU6JRWK=
L-363 NFLudYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTBwNU[2OVch|ryP MoLUV2FPT0WU
BL-41 M4\DTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTBwNU[4PFkh|ryP MoXKV2FPT0WU
LU-134-A NW\J[Yh6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXhTWM2OD1yLkW3NFc{KM7:TR?= NU\pfm9rW0GQR1XS
SIG-M5 MlHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTH[oV4UUN3ME2wMlU4QDR6IN88US=> M3XMNnNCVkeHUh?=
ONS-76 MlTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHYTWM2OD1yLkW4NlQzKM7:TR?= M37MWnNCVkeHUh?=
KARPAS-299 M4jRVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;0cmZKSzVyPUCuOVg2ODRizszN Ml35V2FPT0WU
DU-4475 NVn3PJY6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDWSI5KSzVyPUCuOVg4ODNizszN M3:4WHNCVkeHUh?=
NB69 MlnjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\JTWM2OD1yLkW5PFI2KM7:TR?= M1v4ZnNCVkeHUh?=
MHH-PREB-1 M3\X[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnn0TWM2OD1yLk[wO|E6KM7:TR?= NFTLRoRUSU6JRWK=
LU-165 MofMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;SdGtKSzVyPUCuOlE5OTJizszN NXjoVmJmW0GQR1XS
LOUCY NVzMdG5FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTBwNkOzOlQh|ryP NX7WZot[W0GQR1XS
NCI-H526 NX7HcpZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWn3NGFNUUN3ME2wMlY{PTRzIN88US=> NEPkUldUSU6JRWK=
KE-37 NYjHbHVxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XSfWlEPTB;MD62OFI4PiEQvF2= NGizeW5USU6JRWK=
NALM-6 Ml[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnf4TWM2OD1yLk[0PFYh|ryP NV;vWW1xW0GQR1XS
CW-2 M333U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLwUmRKSzVyPUCuOlU4QTRizszN MYfTRW5ITVJ?
SU-DHL-1 MlH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2X4NGlEPTB;MD62OVk1PyEQvF2= NGS5UlFUSU6JRWK=
NB13 NEX6W5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HkTWlEPTB;MD62OlgyPyEQvF2= M4\IOHNCVkeHUh?=
QIMR-WIL M{Pre2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGm2NplKSzVyPUCuOlg{PDNizszN MYDTRW5ITVJ?
ECC12 NVXy[HZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfze2tKSzVyPUCuO|AxQDZizszN M1PkenNCVkeHUh?=
KALS-1 NEnkfWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTBwN{C0PVIh|ryP M{PiNXNCVkeHUh?=
COR-L279 NFS4O5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnhU|ZZUUN3ME2wMlcxQTl4IN88US=> MkD0V2FPT0WU
NB14 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTBwN{K2NVch|ryP NIPiUW9USU6JRWK=
CCRF-CEM M17wR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fQU2lEPTB;MD63OFY3OSEQvF2= MX7TRW5ITVJ?
SW954 NWX2O|RYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTYRYJKSzVyPUCuO|U6QTlizszN Mmn3V2FPT0WU
IST-SL1 NXjBNotJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1joUmlEPTB;MD63O|M1QCEQvF2= NGK2NZJUSU6JRWK=
LAMA-84 NUewTZJzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfvRpNKSzVyPUCuO|c2PjdizszN M2nVTXNCVkeHUh?=
Daudi M4i2cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVuzdJZxUUN3ME2wMlc4PjhzIN88US=> M1jPU3NCVkeHUh?=
BC-3 M1rUVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rWU2lEPTB;MD63PFMxQCEQvF2= M1fFdHNCVkeHUh?=
HCC2998 M1jmPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;yTWM2OD1yLke4N|Yh|ryP M1nOfHNCVkeHUh?=
NCI-H69 NGrVbmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWn3cZFIUUN3ME2wMlgxOTR5IN88US=> NIf4cVZUSU6JRWK=
CPC-N M3\SeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvNOXVKSzVyPUCuPFA2OjRizszN MnG3V2FPT0WU
NOMO-1 NY\iT5d7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPk[lZ1UUN3ME2wMlgyODh2IN88US=> Mm\nV2FPT0WU
CESS MmLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTBwOEGxPVch|ryP NFXxcmdUSU6JRWK=
LC4-1 Ml7pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWX6fnpIUUN3ME2wMlg1ODB5IN88US=> NF20dXFUSU6JRWK=
BL-70 MmHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnvb5pKSzVyPUCuPFU4ODJizszN MWTTRW5ITVJ?
ES4 NH7ySFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTBwOEW4Olgh|ryP MoXxV2FPT0WU
HCE-T MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTBwOEexO|Eh|ryP NHLOXJdUSU6JRWK=
JAR MkfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPHTWM2OD1yLki3PFI4KM7:TR?= MY\TRW5ITVJ?
ST486 NG\qdZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPmTWM2OD1yLki3PVE4KM7:TR?= MUHTRW5ITVJ?
KS-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTBwOEiwPVYh|ryP MX;TRW5ITVJ?
GDM-1 M4LBWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1O5cmlEPTB;MD64PFY5PyEQvF2= MXzTRW5ITVJ?
EHEB MorDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Moj1TWM2OD1yLkmyOVg2KM7:TR?= M3nVcnNCVkeHUh?=
LB2518-MEL M{nsO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjGTWM2OD1yLkmzNlg1KM7:TR?= NGjVfXNUSU6JRWK=
GOTO MnjKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTBwOUWwO|Yh|ryP MVzTRW5ITVJ?
LXF-289 MljDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{e3OWlEPTB;MD65OVkxOSEQvF2= MnG1V2FPT0WU
ES6 NHrm[YtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DlUWlEPTB;MD65OlQ{PyEQvF2= NHH3XpNUSU6JRWK=
OS-RC-2 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfNRoFKSzVyPUCuPVY5OyEQvF2= MmfrV2FPT0WU
DMS-153 M4TmXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTSTWM2OD1yLkm3OFY6KM7:TR?= M4HVNXNCVkeHUh?=
SK-PN-DW MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4S3fmlEPTB;MD65O|g{OSEQvF2= MmDLV2FPT0WU
HH MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTBwOUi5OVkh|ryP NHSyS41USU6JRWK=
SH-4 MljNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfRTWM2OD1zLkCyOFEh|ryP MofMV2FPT0WU
MOLT-4 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7JNXdKSzVyPUGuNFM1PTRizszN M2DLSnNCVkeHUh?=
TGW NEDoPXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLMeHZ4UUN3ME2xMlA4Pjd3IN88US=> M3\DRnNCVkeHUh?=
L-540 NULCcJFkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTFwMUC2NFQh|ryP M1;ENnNCVkeHUh?=
PF-382 Mo[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXk[Y9KSzVyPUGuNVE2OTNizszN NFfEPHdUSU6JRWK=
LC-1F M2TKeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TwbGlEPTB;MT6xNlAxPyEQvF2= M3jQUnNCVkeHUh?=
OVCAR-4 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDYTWM2OD1zLkGzNVY2KM7:TR?= M2XjN3NCVkeHUh?=
A4-Fuk M2nPbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH65bJJKSzVyPUGuNVU{PjRizszN M2fXbHNCVkeHUh?=
HCC2218 MkHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\KNoFoUUN3ME2xMlE3PjRzIN88US=> M1LycXNCVkeHUh?=
HAL-01 NIXSc4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTFwMU[5OFMh|ryP M4rUe3NCVkeHUh?=
IST-MEL1 M2\hUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEmxVZdKSzVyPUGuNVc3PTlizszN NWHDeFdDW0GQR1XS
NCI-H719 MmDTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jNRWlEPTB;MT6xO|g6QCEQvF2= MWPTRW5ITVJ?
EVSA-T MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;D[3JKSzVyPUGuNVgyOTRizszN M1T2VnNCVkeHUh?=
SK-NEP-1 MlnQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37qd2lEPTB;MT6yNFI3PiEQvF2= NYGzR5JEW0GQR1XS
OCUB-M MnTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13kZWlEPTB;MT6yNVQ5QSEQvF2= MXTTRW5ITVJ?
MEG-01 M1fnfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTFwMkKxNVgh|ryP MoTrV2FPT0WU
no-10 M{PsNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\sTWM2OD1zLkKzNVEzKM7:TR?= NWTJTVRUW0GQR1XS
MHH-CALL-2 NF3vZYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXFSpBKSzVyPUGuNlQ4OjFizszN M3fiTHNCVkeHUh?=
SK-N-DZ NFzpTVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;semlEPTB;MT6yOFc4PiEQvF2= MnjyV2FPT0WU
SCLC-21H NVPMclBNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTFwMk[0O|gh|ryP MWnTRW5ITVJ?
CTV-1 NWPKT3VIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVi4OlJpUUN3ME2xMlI4PDJ3IN88US=> M1fQWnNCVkeHUh?=
NB1 MnXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjwem5KSzVyPUGuNlc4OzJizszN NGm1OVdUSU6JRWK=
NCI-H64 M1niVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX74ZVE3UUN3ME2xMlI5PDZ{IN88US=> NWPjS5VtW0GQR1XS
MDA-MB-134-VI MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XSWGlEPTB;MT6yPFU4PyEQvF2= MXXTRW5ITVJ?
LB2241-RCC MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTFwMki2OlMh|ryP Mn23V2FPT0WU
8-MG-BA MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M162e2lEPTB;MT6yPFg3PiEQvF2= M3;VTnNCVkeHUh?=
LP-1 M2nsWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnf3TWM2OD1zLkK5PVQ4KM7:TR?= M2fkPHNCVkeHUh?=
LS-411N MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHQR|lKSzVyPUGuN|A6QThizszN M1;XZXNCVkeHUh?=
CAL-148 MmLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4Xl[mlEPTB;MT6zNlU1OiEQvF2= NVnHcIp{W0GQR1XS
NCI-H2171 NHmwOoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXjSVBKSzVyPUGuN|Q2ODJizszN MkPsV2FPT0WU
JiyoyeP-2003 NGDvbWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTFwM{WzPUDPxE1? MoDGV2FPT0WU
NCI-H2107 M1XNSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEezV4tKSzVyPUGuN|U5QDNizszN MojZV2FPT0WU
BB30-HNC M3Pofmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTFwM{i5O|gh|ryP NGXU[mFUSU6JRWK=
K-562 MorKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfTTWM2OD1zLkO5NlE6KM7:TR?= NV\jcoxpW0GQR1XS
PSN1 NXX5ZYFCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTFwNEKyPFch|ryP NIDXcI5USU6JRWK=
HCC2157 NH7VTohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\qTWM2OD1zLkSyOlkyKM7:TR?= MUHTRW5ITVJ?
SBC-1 NHn1cFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfwNJZKSzVyPUGuOFI4PDFizszN MWLTRW5ITVJ?
MC116 MoXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HFeWlEPTB;MT60N|YyPSEQvF2= MnK3V2FPT0WU
KARPAS-422 NHTHSVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHf2VlBKSzVyPUGuOFU{PThizszN M1r0S3NCVkeHUh?=
LB996-RCC MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jx[GlEPTB;MT60O|ExOyEQvF2= Mn;pV2FPT0WU
MSTO-211H NWTjb4VbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTFwNEe5PFch|ryP MoLzV2FPT0WU
BT-474 NIfQUnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTFwNUG3OlQh|ryP MkjrV2FPT0WU
A388 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DPdGlEPTB;MT61NVk1PSEQvF2= MYjTRW5ITVJ?
SJSA-1 M3Pje2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDkTWM2OD1zLkWyNlYh|ryP MkH6V2FPT0WU
COLO-829 NVXaWIRVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTFwNUO1OlQh|ryP M2HkcnNCVkeHUh?=
KM-H2 M2S3WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHUTWM2OD1zLkW2Olch|ryP NHzveYtUSU6JRWK=
GR-ST NU\YNVhOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnK5TWM2OD1zLkW2PFIh|ryP NEG5SWdUSU6JRWK=
RPMI-8866 M2K5c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTFwNkCxOFQh|ryP MVPTRW5ITVJ?
KG-1 NW\2SIk{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETKfXFKSzVyPUGuOlE6ODFizszN MWfTRW5ITVJ?
NCI-H82 M4nZ[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrnTWM2OD1zLk[zOFA3KM7:TR?= NVe4XXB[W0GQR1XS
LB1047-RCC NV7ncJFKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTFwNkO0OVkh|ryP MmX5V2FPT0WU
KM12 Mm\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TGTmlEPTB;MT62OFch|ryP M{nzbHNCVkeHUh?=
NB5 NHrIUIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfOe2YxUUN3ME2xMlY2Pjd5IN88US=> M3XQRnNCVkeHUh?=
HDLM-2 NX3EZ2NFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXNOVhKSzVyPUGuOlgzQDFizszN NFq1c5ZUSU6JRWK=
KU812 NFrNPFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTFwNkm2NFUh|ryP MoLSV2FPT0WU
DB MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7pTWM2OD1zLkewN|U{KM7:TR?= NULRNIZUW0GQR1XS
HD-MY-Z NID0SJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{myPGlEPTB;MT63OVI{PCEQvF2= NVH1TGttW0GQR1XS
KURAMOCHI Mn\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTFwN{eyNFch|ryP Mkj5V2FPT0WU
ETK-1 Mk\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTFwN{i4O|kh|ryP MXLTRW5ITVJ?
SK-UT-1 Mk[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4Gxb2lEPTB;MT63PVM5QCEQvF2= MmT5V2FPT0WU
HUTU-80 MmjjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTpeWtDUUN3ME2xMlc6PTB6IN88US=> NIfUfWNUSU6JRWK=
ES7 M1LtXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XiXmlEPTB;MT64NFMxOiEQvF2= MV7TRW5ITVJ?
SW872 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvzOotKSzVyPUGuPFE{QTVizszN MmnjV2FPT0WU
TK10 Mo\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTFwOEOxNFgh|ryP M1[1WHNCVkeHUh?=
LB831-BLC MofaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{L3SmlEPTB;MT64N|U3OyEQvF2= NFnqW5VUSU6JRWK=
TE-9 MmWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvRTWM2OD1zLki0OFIzKM7:TR?= NHz1fnVUSU6JRWK=
MLMA M1;mSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;ze21lUUN3ME2xMlg5OjN2IN88US=> M37TbHNCVkeHUh?=
D-542MG NEjOc5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrxOGRKSzVyPUGuPFk{PzNizszN MUfTRW5ITVJ?
EW-16 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTyWHRTUUN3ME2xMlkzPzJizszN NEezPYZUSU6JRWK=
LOXIMVI NInaUIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rOTmlEPTB;MT65N|I5KM7:TR?= NH21UWxUSU6JRWK=
GB-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrYWYZXUUN3ME2xMlk{QDZ4IN88US=> MoC5V2FPT0WU
IST-SL2 MlXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfZWnhKSzVyPUKuNFAzPjJizszN NVjxboQ3W0GQR1XS
LAN-6 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\RSWlEPTB;Mj6wNVk3PiEQvF2= NFW0dGdUSU6JRWK=
NCI-H510A NUjqTG9CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGj1W2NKSzVyPUKuNFQ2ODJizszN MWnTRW5ITVJ?
NCI-H1092 NWnsVXpjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDxTWM2OD1{LkC1NVI1KM7:TR?= M3j5O3NCVkeHUh?=
HT MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXNTWM2OD1{LkGwOFU1KM7:TR?= MnKzV2FPT0WU
RL95-2 M4\qUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGT0WllKSzVyPUKuNVE1QDJizszN NH;DWYhUSU6JRWK=
NCI-H1355 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTJwMUG3PVIh|ryP MlT2V2FPT0WU
NCI-H720 M{nGTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTSTWM2OD1{LkG2PFc{KM7:TR?= NGXCcJVUSU6JRWK=
NCI-H1522 M2KxdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTJwMkG3NlMh|ryP NWXZR2dLW0GQR1XS
LB373-MEL-D M{O5fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofQTWM2OD1{LkK2PVAzKM7:TR?= M1q2VXNCVkeHUh?=
DG-75 Mo\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXoOHZ2UUN3ME2yMlI4OTR6IN88US=> NEn0V5dUSU6JRWK=
ML-2 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVe1bXp2UUN3ME2yMlMzQDV3IN88US=> M2rJcXNCVkeHUh?=
SF126 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDhTWM2OD1{LkOzNFk1KM7:TR?= M4HadXNCVkeHUh?=
MPP-89 NWPWbnNET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTJwM{OxOFUh|ryP M{ftb3NCVkeHUh?=
NCI-H345 M3rrS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\1VHdKSzVyPUKuN|MzPzdizszN MW\TRW5ITVJ?
LS-123 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3TTWM2OD1{LkO0PVM3KM7:TR?= MoXBV2FPT0WU
NB10 MoPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFWxRVdKSzVyPUKuOFExQTJizszN M{nhbnNCVkeHUh?=
CGTH-W-1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7BTWM2OD1{LkSyNlY4KM7:TR?= Ml\OV2FPT0WU
CP66-MEL M2fxZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkj4TWM2OD1{LkS3O|ch|ryP MnTEV2FPT0WU
L-428 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;PUmNEUUN3ME2yMlQ5PTJzIN88US=> NI[yUodUSU6JRWK=
DMS-79 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnTVpJJUUN3ME2yMlU1OTB|IN88US=> MVHTRW5ITVJ?
NCI-H1882 NFT6OI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTJwNke1OlIh|ryP MknIV2FPT0WU
KGN Mo\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{D2eGlEPTB;Mj63Olg4PiEQvF2= NHTzOIJUSU6JRWK=
EW-1 M{H6U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTJwN{ewPFMh|ryP NGj1RoxUSU6JRWK=
U-266 NHvIWXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXiTWM2OD1{Lki0PFI{KM7:TR?= M3PYdnNCVkeHUh?=
COLO-320-HSR MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;TO2lEPTB;Mj64OVY1OSEQvF2= MkD0V2FPT0WU
KMOE-2 NVLVblV2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvrTWM2OD1{Lki3O|EyKM7:TR?= MlvwV2FPT0WU
BB49-HNC NV;hSZBbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LkTWlEPTB;Mj65NlQ5KM7:TR?= NH:2bHdUSU6JRWK=
GI-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUm2N3N5UUN3ME2yMlkzQTV5IN88US=> NXTu[2dIW0GQR1XS
NCI-H1304 MkHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TmU2lEPTB;Mz6wNFUyOSEQvF2= NGDPTVZUSU6JRWK=
NCI-H2227 NEPLRlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXJTWM2OD1|LkCyNFc6KM7:TR?= NXXCWJpJW0GQR1XS
U-87-MG MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTNwMEO1NVMh|ryP MkHaV2FPT0WU
NCI-H747 NYrOTpd[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XwPGlEPTB;Mz6wOVIxPiEQvF2= M3zYUnNCVkeHUh?=
CTB-1 NILXbIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTNwMEWzO|Yh|ryP M134TXNCVkeHUh?=
RPMI-8226 MnPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLXNoRKSzVyPUOuNVQ{PzhizszN NVfDTndlW0GQR1XS
NCI-H2141 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjVZZVPUUN3ME2zMlE3PTZ4IN88US=> MoH2V2FPT0WU
IST-MES1 NXXUO3VlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzZO4tKSzVyPUOuNVgzPzlizszN NGrabI9USU6JRWK=
TE-5 M{L6OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWqxU2pUUUN3ME2zMlIyOzR{IN88US=> NGO3dYNUSU6JRWK=
UACC-257 NVvS[|V7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{P1WWlEPTB;Mz60N|Y2QSEQvF2= NXTCNJZsW0GQR1XS
SK-N-FI NF\icIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTNwNEWyNlch|ryP MorHV2FPT0WU
MFH-ino NVji[oNqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTNwNE[1PFkh|ryP MWjTRW5ITVJ?
SF268 MlHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3kTWM2OD1|LkS4NVc1KM7:TR?= Mm\OV2FPT0WU
TE-12 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7jTWM2OD1|LkWxOlk6KM7:TR?= NYXsOHpCW0GQR1XS
NB6 M1jydmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXoZW5JUUN3ME2zMlU2PTZ|IN88US=> NHe2OGZUSU6JRWK=
DJM-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTNwNUm4PVkh|ryP NWXrOJh3W0GQR1XS
MZ1-PC M2jYPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTNwNkG2NlQh|ryP NVnqepNnW0GQR1XS
OCI-AML2 NGDLXoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTOTZFOUUN3ME2zMlYzPjdzIN88US=> NXP4VlNEW0GQR1XS
NCI-H1155 NHG2XVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2n1[GlEPTB;Mz63NFk1PyEQvF2= MVHTRW5ITVJ?
RKO NVWwbZNzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\tfWlEPTB;Mz63O|E5QSEQvF2= NUDuNYFqW0GQR1XS
ECC4 NXvJN4tvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTNwOUexPVUh|ryP NUfsVYdbW0GQR1XS
BB65-RCC NULSXFA4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fRb2lEPTB;Mz65O|U1PyEQvF2= Mn;NV2FPT0WU
EB-3 Mmi0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1H3UmlEPTB;Mz65PVY{OyEQvF2= M13P[XNCVkeHUh?=
SHP-77 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nZNmlEPTB;ND6wNFUzPCEQvF2= MUjTRW5ITVJ?
NCI-H2196 MlTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnU[4xPUUN3ME20MlA2PjJ3IN88US=> NHTaNmVUSU6JRWK=
GI-ME-N NGDKXFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LWTWlEPTB;ND6wOlM6QSEQvF2= M1O5Z3NCVkeHUh?=
MN-60 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlL6TWM2OD12LkGwPFch|ryP MVTTRW5ITVJ?
NCI-H1694 MoH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\W[mpKSzVyPUSuNVM1ODVizszN NYXFUVNmW0GQR1XS
LU-65 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DYN2lEPTB;ND6xOVM{OiEQvF2= MYLTRW5ITVJ?
NCI-H1436 NEG0VG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTRwMUizN|Mh|ryP NFfsdlFUSU6JRWK=
KINGS-1 M2TGTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;ETWM2OD12LkOxOFMzKM7:TR?= MX7TRW5ITVJ?
GT3TKB M33MfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUizU4FCUUN3ME20MlM{OjZ6IN88US=> NYDNUmdjW0GQR1XS
Becker M1qyT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;N[otKSzVyPUSuN|c{OTJizszN NGfrc5NUSU6JRWK=
HCC1187 NXvjVFFNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3uTWM2OD12Lki5OlU4KM7:TR?= Mlv6V2FPT0WU
D-502MG MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXuO3dKSzVyPUWuNFA1OTZizszN NWHSbpplW0GQR1XS
VA-ES-BJ NUTMcGhLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfwTWM2OD13LkGzO|c5KM7:TR?= Mnz4V2FPT0WU
NB7 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTVwMUSxNVIh|ryP MnHiV2FPT0WU
SW962 NWi1Z40xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{n4VGlEPTB;NT6zPFgyPCEQvF2= Ml[2V2FPT0WU
no-11 NUH2R5gxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TlSmlEPTB;NT63OlM1OyEQvF2= Moj1V2FPT0WU
KNS-81-FD NX\mdpVWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjOUlVKSzVyPUWuPVA3QTRizszN MmDHV2FPT0WU
COLO-684 M{POdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTVwOUm0PVQh|ryP MUjTRW5ITVJ?
D-263MG M2HW[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvNWXR2UUN3ME22MlA5QDl3IN88US=> NHTZWVZUSU6JRWK=
EW-24 M2nxcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTZwMki1NUDPxE1? NVTGWnhQW0GQR1XS
TE-10 NH7TSmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLaNGRKSzVyPU[uOFI3OjNizszN NWTMfoxFW0GQR1XS
EKVX MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYSyTYF7UUN3ME22MlQ3OzJzIN88US=> MoPKV2FPT0WU
NCI-H1648 NHL0eIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfwTWM2OD14Lk[3OVU4KM7:TR?= M4PVNnNCVkeHUh?=
LB771-HNC MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLGTWM2OD14LkmyN|AyKM7:TR?= MmPCV2FPT0WU
SK-MEL-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjTN5VGUUN3ME24MlE{OTZ4IN88US=> MX;TRW5ITVJ?
COLO-668 NETLTplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjN[nN[UUN3ME24MlI4Pzh4IN88US=> Mnj4V2FPT0WU
EW-12 M{PJcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnCTWM2OD16LkSwPFA{KM7:TR?= NYm4dZBtW0GQR1XS
A253 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\UTWM2OD16Lki0OlYyKM7:TR?= MVfTRW5ITVJ?
NCI-H2126 M17jSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTqTWM2OD16Lki5N|E6KM7:TR?= MYjTRW5ITVJ?
Calu-6 MoDxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfKTWM2OD16Lkm5NFQzKM7:TR?= MXHTRW5ITVJ?
NCI-H23 NE\wSIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3WTWM2OD17LkG3O|Q3KM7:TR?= NWfNUXVxW0GQR1XS
WSU-NHL NHmzVVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlOzTWM2OD17Lke3OFc5KM7:TR?= Mnz1V2FPT0WU
MMAC-SF NWL0fGFjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3y5NmlEPTB;OT65O|kxPCEQvF2= NF\vWFBUSU6JRWK=
SK-LMS-1 NYnjeHl7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTFyLkK4N|Qh|ryP NWnp[25[W0GQR1XS
GCIY MneyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTFyLkW5NlQh|ryP NVXyN2lIW0GQR1XS
TE-15 M1rTXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjmTGxKSzVyPUGxMlYxODRizszN MlLwV2FPT0WU
EoL-1-cell NGf3OnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTFzLke2PFIh|ryP M{\BTXNCVkeHUh?=
NCI-H2081 Ml65S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTFzLke3PFYh|ryP M{jBTHNCVkeHUh?=
EW-3 MmPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXDTWM2OD1zMj6yOFY{KM7:TR?= MWPTRW5ITVJ?
CAS-1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PBSWlEPTB;MUKuN|Y{OSEQvF2= MoflV2FPT0WU
C2BBe1 NITUVWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTF{Lk[xN|Eh|ryP MUXTRW5ITVJ?
D-247MG MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTF{Lke5OVIh|ryP MnW2V2FPT0WU
NCI-SNU-5 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV:1dVh3UUN3ME2xNk45ODF|IN88US=> Ml:2V2FPT0WU
LS-1034 NY\3S2VNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfvR5lKSzVyPUG0MlM6PzVizszN M{nIbHNCVkeHUh?=
EW-18 Mn\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M124[mlEPTB;MUSuOFQ5KM7:TR?= Ml60V2FPT0WU
Raji M3Pze2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3KV3RDUUN3ME2xOE42ODR7IN88US=> NULrWYprW0GQR1XS
D-283MED MmHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfkTWM2OD1zND62NlcyKM7:TR?= NH6yNGRUSU6JRWK=
MZ2-MEL NXH3TmhZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTKSVhMUUN3ME2xOE46Pjl4IN88US=> MoH6V2FPT0WU
NCI-SNU-16 MlKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\ITWM2OD1zNT60OlM{KM7:TR?= NUX0NnppW0GQR1XS
P30-OHK NIjJO4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLJcY9KSzVyPUG3Mlc5OzFizszN MXjTRW5ITVJ?
RXF393 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn:4TWM2OD1zOT6wNVg3KM7:TR?= MnzsV2FPT0WU
NCI-H1395 MljYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1Pxd2lEPTB;MkCuOlcxOyEQvF2= M370b3NCVkeHUh?=
U-698-M MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPKTWM2OD1{MD63NFc2KM7:TR?= MnntV2FPT0WU
NCI-SNU-1 NUPKNIJ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jYXmlEPTB;MkCuO|IzOyEQvF2= NGrscHVUSU6JRWK=
SW684 M3[1[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\ZZ2lEPTB;MkGuNVcyPiEQvF2= M3XRUnNCVkeHUh?=
NCI-H716 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIH3Z|RKSzVyPUKxMlMyPTRizszN M3KyeXNCVkeHUh?=
JVM-2 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjveXhKSzVyPUKxMlQyOzNizszN MmHxV2FPT0WU
NCI-H1581 M1jx[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEGwS4VKSzVyPUKyMlQyPDhizszN NIK5OI9USU6JRWK=
CA46 NH7xTJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHGbmhKSzVyPUOxMlY6OzZizszN MXrTRW5ITVJ?
SNB75 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTN|Lk[1NFMh|ryP MVvTRW5ITVJ?
KNS-42 NUT2b3NHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPxcnhVUUN3ME2zOU46PjJ2IN88US=> Mme3V2FPT0WU
TUR NGfwfldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlG0TWM2OD1|Nj6wOVIyKM7:TR?= NVHJcVRZW0GQR1XS
REH M1m5fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zpR2lEPTB;M{euPFIyOSEQvF2= NHf6OYtUSU6JRWK=
EW-22 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTqTWM2OD12Mj6yPFg2KM7:TR?= MlHuV2FPT0WU
NCI-H446 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFmxbZRKSzVyPUSyMlc5PTNizszN NF3IZXZUSU6JRWK=
ES3 NXTVTYVYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnG5TWM2OD12Mz6xN|M6KM7:TR?= MV7TRW5ITVJ?
EW-11 NID6[XJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXn1dFMzUUN3ME20OE45OjF6IN88US=> M4qwcHNCVkeHUh?=
RH-1 M2roPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjIbYZ{UUN3ME20O{42QDF{IN88US=> Mk[xV2FPT0WU

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ
Methods Test Index PMID
Western blot
AcH3 / AcH4 / HDAC1 / HDAC2 / HDAC3; 

PubMed: 24203492     


HCT-15 or fresh primary NK cells were treated with entinostat for 24 h, and AcH3, AcH4, and HDAC1, 2, and 3 were detected by Western blotting. 

Cleaved PARP; 

PubMed: 19148581     


Induction of PARP cleavage in Daoy cells upon exposure to MS-275 was demonstrated by Western blot analyses using antibodies that recognize the cleaved 89 kDa PARP protein. Pan-Actin (45 kDa) was used as a loading control.

Caspase 8 ; 

PubMed: 19148581     


Cleavage of pro-Caspase-8 was demonstrated by Western blotting with extracts prepared from Daoy cells treated with 2.5 µM MS-275 for various time periods. Antibodies specific to human Caspase-8 or the loading control, pan-Actin were used to probe protein expression.

DR4 / DR5; 

PubMed: 19148581     


Western blotting to detect DR4 and DR5 expression upon treatment of Daoy cells with 2.5 µM MS-275 for 4, 8 and 24 h.

TopoIIα / TopoIIβ; 

PubMed: 21254166     


Upper panel, concentration-dependent effects of AR42, MS-275 and vorinostat on the expression of topoIIα versus topoIIβ after 48 h. Lower panel, time-dependent effect of 0.5 μM AR42 and 5 μM MS-275 on topoIIα versus topoIIβ expression in PLC-5 cells.

24203492 19148581 21254166
Immunofluorescence
phalloidin / snail; 

PubMed: 29855565     


(C) Effect of MS-275 treatment on Snail expression and localization. MCs (mesothelial cells) were treated with MS-275 (250 nM), or DMSO for 48 hr and then stimulated with TGFβ1 (2 ng/ml) for 24 h before processing for immunofluorescence with a monoclonal antibody against Snail. Cell nuclei are shown in blue (Hoechst 33342). Confocal images are shown from one representative experiment of three performed.

DR4 / DR5; 

PubMed: 19148581     


Flow Cytometry to measure cell surface expression of FAS, DR4 and DR5 using PE-labeled antibodies. Cells stained with isotype matched anti-human IgG antibodies served as controls.

H3K4Me3 / H3K9Me3; 

PubMed: 22468166     


Immunocytochemical analysis of the effects of AR42, SAHA, and MS-275 at the indicated concentrations on H3K4Me3 (upper panels) and H3K9Me3 (lower panels) after 24 h of treatment in LNCaP cells.

29855565 19148581 22468166
Growth inhibition assay
Cell proliferation; 

PubMed: 24203492     


(A) HCT-15 cells were cultured in indicated concentrations of entinostat for up to 72 h, and proliferation determined by MTT assay as indicated. (B) HCT-15, CCH-OS-D, COL and HOS cells were cultured in indicated concentrations of entinostat for 72 h, and viable cell number was determined using the Vi-cell assay and proliferation index calculated. (C) Freshly-isolated human NK cells were cultured in indicated concentrations of entinostat for up to 72 h, and viability was assessed by flow cytometry for 7-AAD uptake. *, P < 0.05, **; P ≤ 0.01; ***, P ≤ 0.001

Cell viability; 

PubMed: 28969017     


PANC-1, MIA PaCa-2, BxPC3, CFPAC-1, SUIT2 and SUIT2 Clone 1 cells were plated at a density of 3-5×103 per well in 96-well microtiter plates, allowed to adhere overnight and incubated for 72 hours in the presence of variable concentrations of entinostat (0-100μM). Cell viability was determined by XTT assays. The data presented are the mean values from triplicate wells from two independent experiments ±SE.

24203492 28969017
ELISA
GCP-2 / MCP-2 / MIF ; 

PubMed: 24241152     


MS-275 and SAHA suppressed the secretion of GCP-2, MCP-2 and MIF in E11 cells. (A) GCP suppression. (B) MCP-2 suppression. (C) MIF suppression. E11 cells were incubated with HDAC inhibitors at various concentrations for 1 h before they were stimulated by LPS. 24 h later, the secretion of GCP-2, MCP-2 and MIF were quantified by ELISA (n = 8). Bars show the mean and SD in (A–C).

24241152
体内試験 MS-275 exhibits great antitumor activity against human tumor xenografts except HCT-15 at 49 mg/kg. [1] MS-275 demonstrates promising therapeutic potential in both solid and hematologic malignancies, as well as regulation of physiologic and aberrant gene expression. [4] MS-275, combination with IL-2, has great antitumor activity to renal cell carcinoma xenograft model, which due to decreased T regulatory cells and increased splenocytes. [5]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[6]

+ 展開

Standard HDAC Assays:

Rat liver enzyme is diluted 1:6 with HDAC buffer. Recombinant human HDACs are diluted 1:4 in HDAC buffer. For standard HDAC assays, 60 μL of HDAC buffer is mixed with 10 μL of diluted enzyme solution at 30 °C. The HDAC reaction is started by adding 30 μL substrate solution in HDAC buffer followed by 30 min of incubation at 30 °C. The reaction is stopped by adding 100 μL trypsin solutions (10 mg/ml trypsin in 50 mM Tris-HCl [pH 8.0], 100 mM NaCl, 2 μM TSA). After a 20 min incubation period at 30 °C, the release of AMC is monitored by measuring the fluorescence at 460 nm (λex = 390 nm). Fluorescence intensity is calibrated using free AMC. For standard time course experiments, 20 pmol of substrate is used in the initial 100 μL HDAC reaction. Km and Vmax values are determined by measuring the fluorescence AMC generated by enzymatic cleavage of 2–50 pmol of substrate. The experimental data are analyzed using a Hanes plot. The AMC signals are recorded against a blank with buffer and substrate but without the enzyme.
細胞試験:

[2]

+ 展開
  • 細胞株: A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 cells
  • 濃度: ~ 10 μM
  • 反応時間: 3 days
  • 実験の流れ:

    Cancer cells (5 × 103) are seeded into each well of 96-well plates and cultured with graded concentrations of MS-275 for 3 days. The cells are stained with 0.1 mg/mL neutral red for 1 hour in a CO2-incubator, and, after aspiration of the medium, OD540 of the neutral red solubilized with 50 μL of ethanol and 150 μL of 0.1 M Na2HPO4 is measured. The IC50 value is determined by plotting growth inhibition of the cells against the logarithm of the drug concentration.


    (参考用のみ)
動物試験:

[1]

+ 展開
  • 動物モデル: A2780, HT-29, HTC-15, KB-3-1, 4-1St, St-4, Capan-1 and Calu-3 cells are injected subcutaneously into the flank of nude mice.
  • 製剤: Dissolved with 0.05 N HCl, 0.1% Tween 80
  • 投薬量: 12.3, 24.5 and 49 mg/kg
  • 投与方法: Administered orally once daily 5 days per week for 4 weeks
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 75 mg/mL (199.25 mM)
Water Insoluble
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
2% DMSO+30% PEG 300+ddH2O
混合させたのち直ちに使用することを推奨します。
10mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 376.41
化学式

C21H20N4O3

CAS No. 209783-80-2
保管
in solvent
別名 SNDX-275

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03838042 Not yet recruiting CNS Tumor|Solid Tumor University Hospital Heidelberg|German Cancer Research Center March 2019 Phase 1|Phase 2
NCT03829930 Not yet recruiting Prostate Adenocarcinoma George Washington University March 1 2019 Phase 1
NCT03765229 Recruiting Melanoma UNC Lineberger Comprehensive Cancer Center|Syndax Pharmaceuticals Inc. March 2019 Phase 2
NCT03838042 Not yet recruiting CNS Tumor|Solid Tumor University Hospital Heidelberg|German Cancer Research Center March 2019 Phase 1|Phase 2
NCT03829930 Not yet recruiting Prostate Adenocarcinoma George Washington University March 1 2019 Phase 1
NCT03765229 Recruiting Melanoma UNC Lineberger Comprehensive Cancer Center|Syndax Pharmaceuticals Inc. March 2019 Phase 2

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    I would like to use Entinostat(Catalog No.S1053) for animal study. What is your recommendation for the solvent? What is the role of PEG 300 in this case? Can I use DMSO only and dilute it with PBS or HBSS?

  • 回答:

    2%DMSO/30%PEG/68%Water is recommended. PEG is an important polymer that helps with the solubility of hydrophobic drugs. If you use DMSO only and dilute it with PBS or HBSS, Entinostat will likely to precipitate out since it has very low solubility in water.

HDACシグナル伝達経路

HDAC Inhibitors with Unique Features

相関HDAC製品

Tags: Entinostat (MS-275)を買う | Entinostat (MS-275) ic50 | Entinostat (MS-275)供給者 | Entinostat (MS-275)を購入する | Entinostat (MS-275)費用 | Entinostat (MS-275)生産者 | オーダーEntinostat (MS-275) | Entinostat (MS-275)化学構造 | Entinostat (MS-275)分子量 | Entinostat (MS-275)代理店
×

平素は格別のお引き立てを賜り厚くお礼申し上げます。
国内在庫の無い製品の輸入手配は通常、毎週木曜12時で締め切らせていただいておりますが、
9月第2週の輸入手配に関しましては都合により締切日を9月10日(火)12時とさせていただきます。
お客様には大変ご不便をお掛けいたしますが、よろしくお願い申し上げます。

×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID